Renal & Urinary

SGLT2 inhibitors in chronic kidney disease

Clinical Overview and When to Suspect CKD Benefit from SGLT2 Inhibitors

— CREDENCE (canagliflozin): T2DM + albuminuric CKD, reduced ESKD, doubling of creatinine, renal/CV death

— DAPA-CKD (dapagliflozin): CKD with or without diabetes, eGFR 25–75, UACR 200–5000

— EMPA-KIDNEY (empagliflozin): broader CKD population including eGFR down to 20 and non-albuminuric CKD

— Adult with eGFR ≥20 mL/min/1.73 m² and CKD (G1–G4) with UACR ≥200 mg/g, OR

— Diabetic kidney disease at any albuminuria level once eGFR ≥20, OR

— CKD with HF or atherosclerotic CVD regardless of diabetes status

Board pearl: If a Step 3 stem describes a stable CKD patient on a maxed ACEi with persistent albuminuria, the answer is almost always add an SGLT2 inhibitor before escalating to nephrology or considering dual RAAS blockade (which is contraindicated).

SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin, ertugliflozin) block sodium-glucose cotransporter-2 in the proximal tubule, producing glucosuria, natriuresis, and tubuloglomerular feedback-mediated afferent arteriolar constriction that lowers intraglomerular pressure

Originally approved for type 2 diabetes glycemic control, now established as disease-modifying therapy for CKD (with or without diabetes), HFrEF, and HFpEF

Landmark trials shaping Step 3 practice:

When to suspect a patient benefits:

Typical Step 3 vignette: outpatient T2DM patient on ACEi/ARB with UACR 350 mg/g and eGFR 48 — next best step is adding an SGLT2 inhibitor, not titrating sulfonylurea

Layered on top of, not in place of, RAAS blockade (ACEi or ARB at maximally tolerated dose); together with finerenone in diabetic CKD they form the "pillars" of kidney protection

Effects are largely glucose-independent: BP reduction ~3–5 mmHg, weight loss 2–3 kg, ~30–40% reduction in albuminuria, ~30% reduction in CKD progression composite

Presentation Patterns and Key History

— Pattern A — Diabetic kidney disease: T2DM ≥5 years, A1c 7–9%, hypertension, UACR rising despite lisinopril 40 mg, eGFR drifting from 70 → 50 over 3 years

— Pattern B — Non-diabetic proteinuric CKD: IgA nephropathy, FSGS, or hypertensive nephrosclerosis with persistent UACR >200 on ARB

— Pattern C — HF + CKD overlap: HFrEF EF 30%, eGFR 35, volume overload episodes — SGLT2i serves both axes

— Pattern D — Recently hospitalized for HF or AKI-resolved CKD: post-discharge optimization visit

— Volume status and diuretic dose (risk of symptomatic hypotension if euvolemic on loop diuretic)

— Recurrent UTI or genital mycotic infection history (relative caution, not absolute contraindication)

— DKA risk factors: type 1 diabetes (contraindicated), pancreatic insufficiency, very low-carb diet, prior DKA, heavy alcohol use

— Foot ulcers, peripheral vascular disease, prior amputation (historical canagliflozin signal; clinically de-emphasized but still asked)

— Planned surgery within 3–4 days (hold to prevent euglycemic DKA)

— Adherence to sick-day rules capacity

Step 3 management: Before prescribing, document baseline eGFR, UACR, K⁺, volume status, and patient understanding of sick-day rules (hold for NPO, severe illness, vomiting, or 3 days pre-op) — this is the "perioperative and transitions-of-care" thinking Step 3 rewards over Step 2's pure pharmacology recall.

SGLT2 inhibitor decisions are made in ambulatory continuity visits, not ED encounters — Step 3 emphasizes the longitudinal management lens

Typical candidate profiles:

Key history to elicit before initiation:

Medication reconciliation: insulin, sulfonylureas (hypoglycemia risk when A1c near goal — anticipate dose reduction of insulin by ~20% and SU by 50%), loop diuretics (consider 50% dose reduction if euvolemic)

Physical Exam Findings and Hemodynamic Assessment

— Seated and standing BP — orthostasis (>20 mmHg systolic drop) suggests volume depletion; defer initiation or reduce diuretic first

— Resting HR — tachycardia may signal compensatory hypovolemia

— Weight (baseline for monitoring 2–3 kg expected loss)

— JVP at 30–45° — flat JVP + low BP = hypovolemic, hold initiation

— Mucous membranes, skin turgor in elderly

— Lower extremity edema — pitting edema in CKD/HF patient suggests euvolemic-to-hypervolemic, good candidate

— Lung auscultation for rales (HF overlap)

— Perineal/genital inspection in patients with diabetes — baseline for monitoring Fournier gangrene (rare but FDA black-box) and candidal infections

— Foot exam in diabetics: ulcers, calluses, pulses, monofilament testing — document before starting

— S3, displaced PMI suggest HF — SGLT2i benefits both CKD and HF axes

— Carotid bruits, AAA palpation in vasculopaths

— CCS pearl: For inpatient initiation of SGLT2i in stabilized HF or CKD, confirm patient is off IV diuretics, tolerating PO, eGFR ≥20, K⁺ <5.5, and not septic or peri-AKI before clicking "order empagliflozin 10 mg daily" — initiation during active AKI or sepsis is a wrong-answer trap

Board pearl: A patient with eGFR 22, UACR 800, BP 128/76, no orthostasis, mild bipedal edema is the textbook initiation candidate — start empagliflozin 10 mg daily.

SGLT2i candidates are typically outpatient and well-appearing; the exam goal is to confirm euvolemia and rule out states where initiation would precipitate harm

Vital signs to document:

Volume assessment:

Skin and GU exam:

Cardiac:

In hospitalized patients (CCS scenarios):

Hemodynamic principle: SGLT2i causes mild osmotic diuresis (~300 mL/day) plus natriuresis — additive with loop diuretics but unlike loops, preserves interstitial-to-vascular fluid ratio, explaining lower orthostasis risk than equivalent diuretic uptitration

Diagnostic Workup — Initial Labs to Confirm Candidacy

— Serum creatinine and eGFR (CKD-EPI 2021, race-free equation) — initiate if eGFR ≥20 mL/min/1.73 m²

— Continue SGLT2i once started even if eGFR falls below 20 down to dialysis initiation (per EMPA-KIDNEY and KDIGO 2024) — do NOT discontinue for eGFR decline alone

— Spot urine albumin-to-creatinine ratio (UACR) — establishes proteinuric vs non-proteinuric CKD; both benefit but magnitude greater with UACR >200

— Serum K⁺ (SGLT2i is mildly potassium-neutral to lowering, helpful when combining with ACEi/ARB/finerenone)

— Bicarbonate (baseline for DKA monitoring; low HCO₃ + osmotic diuresis raises caution)

— Sodium, chloride, anion gap

— A1c (for T2DM patients; expect 0.5–0.7% drop)

— Fasting glucose

— In type 1 diabetes — do not initiate (euglycemic DKA risk prohibitive)

— NT-proBNP if HF suspected

— Weight, BP

— Urinalysis (asymptomatic bacteriuria does NOT require treatment or preclude initiation)

— LFTs (no hepatic dose adjustment needed for most; avoid in severe hepatic impairment for canagliflozin)

— Recheck BMP at 2–4 weeks, then 3 months, then with usual CKD cadence

— Discontinuation triggers: persistent eGFR drop >30% from baseline (uncommon), hyperkalemia attributable to other meds, recurrent DKA, Fournier gangrene

Key distinction: An initial eGFR dip on starting an SGLT2i is expected and reassuring, analogous to the ACEi dip — do not stop the drug. Stopping for the dip is a classic Step 3 wrong answer.

Before prescribing, obtain a baseline panel that anchors both eligibility and future monitoring

Renal function:

Electrolytes and acid-base:

Glycemic:

Volume and cardiac markers (when relevant):

Safety screens:

Expected "initiation dip": eGFR may drop 3–5 mL/min/1.73 m² within 2–4 weeks — this is hemodynamic (afferent constriction), not nephrotoxicity, and predicts long-term benefit

Diagnostic Workup — Advanced and Confirmatory Studies

— Two eGFR values ≥3 months apart to confirm chronicity

— Cystatin C-based eGFR when creatinine is unreliable (sarcopenia, amputation, bodybuilders) — supported by KDIGO 2024

— Quantitative 24-hour urine protein if UACR is borderline or nephrotic-range proteinuria suspected

— Diabetic retinopathy on dilated fundus exam supports diabetic nephropathy as cause (high specificity)

— Serologies: ANA, ANCA, anti-GBM, complements, SPEP/UPEP, hepatitis B/C, HIV when glomerular disease suspected

— Renal ultrasound: size, echogenicity, obstruction; small echogenic kidneys = chronic disease

— Kidney biopsy if rapidly progressive, hematuria with proteinuria, atypical features — does not delay SGLT2i initiation

— ECG, echocardiogram if HF symptoms — many CKD patients have unrecognized HFpEF that independently indicates SGLT2i

— Lipid panel for ASCVD risk stratification

— C-peptide if latent autoimmune diabetes (LADA) suspected in a "T2DM" patient with low BMI, rapid insulin need, or autoantibodies — these patients behave like T1DM and should not get SGLT2i

— BMP at 2–4 weeks (eGFR, K⁺, HCO₃)

— A1c, UACR at 3 months — UACR reduction of 30%+ is a favorable response biomarker

— Annual lipids, repeat UACR

Board pearl: A T2DM patient on SGLT2i presents with nausea, malaise, glucose 180, anion gap 22, ketones positive, pH 7.25 — diagnose euglycemic DKA, hold the drug, start IV fluids + insulin + dextrose. Normal glucose does not exclude DKA on SGLT2i.

Most SGLT2i decisions require no advanced testing beyond the basic CKD workup — but Step 3 questions often layer in workup of the underlying CKD etiology because therapy is shared but prognosis differs

Confirming CKD diagnosis and staging:

Etiology workup when unclear:

Cardiovascular co-assessment:

DKA risk pre-screen in selected patients:

Monitoring labs after initiation:

Risk Stratification and First-Line Management Logic

— Pillar 1: RAAS blockade — ACEi or ARB at maximally tolerated dose for any UACR ≥30, titrated until K⁺ or symptomatic hypotension limits

— Pillar 2: SGLT2 inhibitor — for eGFR ≥20 with UACR ≥200 (any CKD) or with T2DM (any albuminuria)

— Pillar 3: Nonsteroidal MRA (finerenone) — for T2DM + CKD with persistent albuminuria despite pillars 1 and 2, K⁺ ≤4.8, eGFR ≥25

— Pillar 4: GLP-1 receptor agonist (semaglutide, liraglutide) — for T2DM with CKD, especially obesity or ASCVD; FLOW trial supports kidney benefit

— Combines eGFR category (G1–G5) with albuminuria category (A1–A3)

— Red zone (e.g., G3b/A3, G4/A2-3) = highest risk for ESKD and CV events = strongest SGLT2i mandate

— Type 1 diabetes (DKA risk)

— eGFR <20 for initiation (continuation allowed)

— Prior DKA, recurrent genital infections (relative)

— Pregnancy and breastfeeding

— Active foot infection or critical limb ischemia (case-by-case)

— BP <120/80 if tolerated (per KDIGO, SPRINT-informed)

— A1c individualized: 7% for most, 7.5–8% if frail or limited life expectancy

Step 3 management: When asked "what is the next best step" for a T2DM patient with eGFR 45, UACR 400, on lisinopril 40 + amlodipine, A1c 7.2%, K⁺ 4.5 — the answer is add empagliflozin 10 mg daily, not intensify glycemic control, not start statin (likely already on), not refer to nephrology.

KDIGO 2024 and ADA 2024 organize CKD management as four pillars, layered sequentially but rapidly:

Risk stratification using KDIGO heat map:

Sequencing principle: Do not wait months between pillars; in stable outpatients, add the next pillar at the next visit (4–6 weeks) after confirming labs are tolerable

Contraindications to remember:

BP and glycemic targets layered alongside:

Pharmacotherapy — Agents, Dosing, and Drug Selection

— Empagliflozin (Jardiance) — 10 mg PO daily; CKD indication regardless of diabetes; broadest eGFR range (≥20)

— Dapagliflozin (Farxiga) — 10 mg PO daily; CKD indication regardless of diabetes; eGFR ≥25 for initiation per label, ≥20 per guidelines

— Canagliflozin (Invokana) — 100 mg PO daily (max 300 mg for glycemic effect); diabetic kidney disease indication; historical amputation signal

— Ertugliflozin — primarily glycemic indication, weaker kidney/CV evidence; not first-line for CKD protection

— Empagliflozin is the workhorse Step 3 answer — broadest indications (CKD, HFrEF, HFpEF, T2DM, ASCVD risk reduction)

— Dapagliflozin is equally appropriate for CKD and HF

— Canagliflozin preferred only when CREDENCE-specific population (T2DM + albuminuric CKD) and no amputation risk

— Same dose across eGFR ranges (unlike metformin)

— Glycemic efficacy wanes as eGFR drops, but cardiorenal benefit persists down to dialysis

— Loop diuretics: synergistic diuresis — reduce furosemide by 25–50% at initiation if euvolemic

— Insulin/sulfonylureas: hypoglycemia risk — reduce insulin ~20%, SU by 50%

— ACEi/ARB: synergistic BP lowering — monitor for orthostasis

— Lithium: SGLT2i increases lithium clearance — monitor levels

— No interaction with warfarin, DOACs, statins

— Sick-day rules: Hold for NPO, surgery, severe vomiting/diarrhea, hospitalization for acute illness

— Perioperative hold: 3 days before elective surgery (4 days for ertugliflozin)

— Genital hygiene to reduce mycotic infection

— Adequate hydration but no need to force fluids

— Recognize DKA symptoms: nausea, malaise, abdominal pain — seek care even if glucose normal

Board pearl: Empagliflozin 10 mg daily is the single most asked SGLT2i answer on Step 3 — memorize the indications (CKD eGFR ≥20, HFrEF, HFpEF, T2DM + ASCVD).

FDA-approved SGLT2 inhibitors with kidney indications:

Drug selection logic:

Dosing in CKD — no titration needed:

Drug-drug interactions:

Counseling points (Step 3 loves these):

Expanded Pharmacology — Mechanism, Monitoring, and Combination Therapy

— Tubuloglomerular feedback restoration: Glucose and Na⁺ delivery to macula densa increases → afferent arteriolar constriction → reduced intraglomerular hypertension

— Reduced hyperfiltration → less podocyte stress and slower GFR decline

— Natriuresis and mild osmotic diuresis → preload reduction → benefit in HF

— Reduced tubular workload and oxygen consumption → less cortical hypoxia

— Modest weight loss, BP reduction, uric acid lowering

— Shift to ketone utilization as cardiac fuel (proposed HF mechanism)

— ACEi/ARB + SGLT2i + finerenone + GLP-1 RA is the contemporary maximal regimen

— Each adds independent and additive kidney protection (FIDELIO-DKD, FLOW)

— Sequence: maximize ACEi/ARB → add SGLT2i → add finerenone if K⁺ ≤4.8 → add GLP-1 RA if A1c or weight remain off-target

— SGLT2i is K⁺-neutral or lowering, mitigating ACEi/MRA hyperkalemia

— If K⁺ 5.0–5.5: dietary counseling, loop diuretic dose review, consider patiromer or sodium zirconium cyclosilicate to maintain RAAS therapy

— A1c reduction modest (0.3–0.7%) and diminishes as eGFR falls (less filtered glucose to block)

— Below eGFR 30, SGLT2i is not a glucose-lowering drug but remains a kidney/CV drug

— Pair with metformin (if eGFR ≥30) or GLP-1 RA for glycemic targets

— Brand-only currently (no generics yet in US); ~$600/month

— Medicare Part D coverage variable; prior authorization common

— Patient assistance programs and manufacturer co-pay cards reduce out-of-pocket

Step 3 management: When a diabetic CKD patient on lisinopril + empagliflozin still has UACR 600 mg/g and K⁺ 4.4, add finerenone 10 mg daily — this is the textbook fourth-line layering, with recheck K⁺ in 4 weeks.

Mechanism of kidney protection (multifactorial, exam-favorite):

Combination strategy in diabetic CKD:

Hyperkalemia management when stacking:

Glycemic considerations:

Cost and access (Step 3 systems thinking):

Special Populations — Elderly and Renal/Hepatic Impairment

— SGLT2i benefits preserved across age groups (EMPA-KIDNEY, DAPA-CKD subgroup analyses)

— Increased vigilance for:

– Volume depletion and orthostasis — start with diuretic dose reduction

– Falls — assess gait, vision, polypharmacy

– Genital mycotic infections — counsel on hygiene, especially women with atrophic vaginitis

– Mild cognitive impairment affecting sick-day rule adherence — involve caregivers

— Do NOT withhold for age alone if eGFR and volume status appropriate

— eGFR ≥20: initiate

— eGFR <20 or on dialysis: do not initiate (insufficient data, though trials ongoing)

— Already on SGLT2i with eGFR drift below 20: continue until dialysis initiation per KDIGO 2024

— Post-kidney transplant: emerging data favorable but not yet standard of care; specialist decision

— AKI episodes: hold during acute hospitalization, restart at discharge when stable and euvolemic

— Mild–moderate (Child-Pugh A–B): no dose adjustment for empagliflozin or dapagliflozin

— Severe (Child-Pugh C): avoid canagliflozin; empagliflozin and dapagliflozin used cautiously, limited data

— Watch for DKA risk in cirrhotic patients with poor PO intake or sarcopenia

— Benefit emerges within months for HF, 1–2 years for kidney endpoints

— Reasonable to continue in patients with prognosis >1 year; deprescribe in active hospice transitions

— Review at each visit for NSAIDs (additive AKI risk), iodinated contrast (hold periprocedure), and recent antibiotic-induced GI losses

Board pearl: An 82-year-old with eGFR 24, UACR 500, BP 122/70, on lisinopril and low-dose furosemide is still an SGLT2i candidate — start empagliflozin 10 mg daily and reduce furosemide by half.

Elderly (≥75 years):

Renal impairment — the central population:

Hepatic impairment:

Frailty and limited life expectancy:

Polypharmacy reconciliation:

Special Populations — Pregnancy, Pediatrics, and Other Subgroups

— SGLT2 inhibitors are contraindicated in pregnancy (animal data show fetal renal abnormalities in second/third trimester)

— Discontinue before conception in patients planning pregnancy

— For pregnant patients with diabetic kidney disease, switch to insulin for glycemia; ACEi/ARB also stopped — use labetalol, nifedipine, methyldopa, hydralazine for BP

— Postpartum, can resume SGLT2i if not breastfeeding

— Avoid; theoretical risk to neonatal kidney development

— Decision balances maternal benefit and infant exposure — generally hold during lactation

— Empagliflozin and dapagliflozin approved for T2DM in children ≥10 years

— No pediatric CKD indication yet; specialist-driven decisions

— T1DM in adolescents: not approved (DKA risk)

— Contraindicated for kidney protection in T1DM in the US (despite some international approvals for glycemic adjunct)

— Step 3 trap: T1DM patient with CKD asks about empagliflozin — answer is do not start; intensify insulin and ACEi

— Active research; case series suggest safety in stable kidney transplant recipients with eGFR ≥30

— Not standard of care; defer to transplant nephrology

— No specific contraindication; monitor for genital infections more closely

— Ketogenic diet or bariatric surgery patients: elevated euglycemic DKA risk — counsel carefully or avoid

— Heavy alcohol use: increased DKA risk; counsel reduction

— Eating disorders: avoid (DKA and dehydration risk)

Key distinction: Type 1 diabetes is an absolute contraindication; type 2 diabetes with insulin use is not — the latter benefits substantially but requires DKA counseling and insulin dose adjustment of ~20%.

Pregnancy:

Breastfeeding:

Pediatrics:

Type 1 diabetes:

Post-transplant:

HIV, hepatitis, immunosuppressed:

Special situations:

Complications and Adverse Outcomes

— Incidence ~0.1–0.6% in T2DM, higher with insulin deficiency, illness, surgery, low-carb diets

— Presentation: nausea, vomiting, abdominal pain, malaise, glucose often <250 but anion-gap acidosis with ketonemia

— Management: hold SGLT2i, IV fluids, insulin infusion with concurrent dextrose (because glucose is normal), monitor anion gap closure

— Prevention: sick-day rules, perioperative hold 3–4 days

— More common in elderly, on loop diuretics, on ACEi

— Initial eGFR dip of 3–5 is expected and reversible; persistent >30% drop warrants workup

— Hold during acute illness with poor PO intake

— Vulvovaginal candidiasis (~10% women), balanitis (~3% men)

— Treat with topical/oral antifungals; do not discontinue for first episode

— Recurrent infections: consider switching agent or discontinuation

— Modest increase, especially uncomplicated cystitis

— Pyelonephritis and urosepsis rare but reported

— FDA black-box warning; very rare but life-threatening

— Presents with perineal pain, swelling, fever, rapid progression

— Emergent surgical debridement + broad-spectrum antibiotics + permanent SGLT2i discontinuation

— Original CANVAS canagliflozin signal; not confirmed in subsequent trials or with other agents

— Reasonable caution in patients with prior amputation or active foot ulcer

— Older signal, not robust with empagliflozin/dapagliflozin

— Rare with SGLT2i monotherapy; common when combined with insulin or sulfonylureas — anticipate dose reductions

CCS pearl: A patient on empagliflozin presents with abdominal pain, nausea, glucose 190, HCO₃ 14, anion gap 20, β-hydroxybutyrate elevated — order ICU admission, IV NS, insulin drip 0.1 U/kg/hr with D5W concurrent, hold SGLT2i permanently if recurrent.

Euglycemic diabetic ketoacidosis (eDKA):

Volume depletion and AKI:

Genital mycotic infections:

Urinary tract infections:

Fournier gangrene (necrotizing fasciitis of perineum):

Lower-extremity amputation:

Bone fracture risk (canagliflozin):

Hypoglycemia:

When to Escalate Care — Consult, Inpatient, ICU

— eGFR <30 with rapidly declining trajectory (>5 mL/min/yr)

— Nephrotic-range proteinuria (UACR >3000) or unclear CKD etiology

— Refractory hyperkalemia limiting RAAS/MRA therapy

— Preparation for kidney replacement therapy at eGFR <20

— Hereditary kidney disease, suspected glomerulonephritis

— Recurrent DKA on SGLT2i

— Suspected LADA misclassified as T2DM

— Complex insulin regimens needing optimization

— Euglycemic DKA — admission, often ICU if pH <7.25 or hemodynamically unstable

— Fournier gangrene — emergent surgical consult, ICU, broad-spectrum antibiotics

— Severe AKI with oliguria, hyperkalemia, uremia — hold SGLT2i, evaluate cause

— Severe symptomatic hypotension or syncope

— Sepsis from urosepsis or any source — hold SGLT2i

— DKA with pH <7.0, hemodynamic instability, altered mental status

— Necrotizing soft-tissue infection

— Severe hyperkalemia (K⁺ >6.5 with ECG changes)

— Hold on admission for any acute illness, NPO status, contrast exposure, or surgery

— Restart at discharge if stable, euvolemic, eating, eGFR ≥20

— Document hold and restart plan in discharge summary — transition-of-care failure is a common Step 3 patient-safety theme

— HF decompensation: SGLT2i typically continued during hospitalization in stable HF (EMPULSE supports in-hospital initiation in stabilized acute HF)

Step 3 management: A patient admitted for cellulitis with mild AKI on chronic dapagliflozin — hold dapagliflozin during hospitalization, restart on discharge with PCP follow-up in 2 weeks and BMP recheck.

Most SGLT2i management is outpatient, but several triggers mandate escalation

Nephrology referral (outpatient, urgent):

Endocrinology referral:

ED/inpatient triage:

ICU criteria:

Hospital management of patients on chronic SGLT2i:

Cardiology overlap:

Key Differentials — Same-Category Causes of CKD Progression

— Confirm patient is on maximally tolerated ACEi or ARB (e.g., lisinopril 40, losartan 100)

— Adherence check, BP at goal

— Avoid dual RAAS blockade (ACEi + ARB or + direct renin inhibitor) — increases AKI and hyperkalemia without benefit (ONTARGET, ALTITUDE)

— Nonsteroidal MRA proven in FIDELIO-DKD and FIGARO-DKD

— Add when K⁺ ≤4.8 and eGFR ≥25 in T2DM + albuminuric CKD on RAAS + SGLT2i

— Distinct from spironolactone/eplerenone (steroidal MRAs) — finerenone has less hyperkalemia and gynecomastia, more cardiorenal selectivity

— Semaglutide (FLOW trial) showed kidney composite benefit in T2DM + CKD

— Adds independent renoprotection plus weight and glycemic benefits

— Especially valuable when obesity is a driver

— Target <120/80 if tolerated (KDIGO)

— Add chlorthalidone or amlodipine if BP uncontrolled

— A1c 7% for most T2DM with CKD; individualize for frailty

— 0.6–0.8 g/kg/day in non-dialysis CKD; not a substitute for pharmacotherapy

Board pearl: A T2DM patient on lisinopril 40 + empagliflozin 10 still has UACR 700 and K⁺ 4.3 — add finerenone 10 mg daily, not switch SGLT2i or add ARB.

When albuminuria or eGFR decline persists despite SGLT2i, consider other CKD-modifying interventions within the renoprotective category

Inadequate RAAS blockade:

Finerenone underuse:

GLP-1 receptor agonists:

Blood pressure optimization:

Glycemic control:

Dietary protein moderation:

Smoking cessation, weight loss, sodium restriction (<2 g/day)

Key Differentials — Other-Category Causes of Renal Decline

— Prerenal: volume depletion from SGLT2i diuresis + loop diuretic + GI losses or NSAIDs — most common

— Intrinsic: contrast nephropathy, ATN from sepsis, allergic interstitial nephritis (PPI, antibiotics)

— Postrenal: obstruction — BPH, stones, malignancy — confirm with renal ultrasound

— IgA nephropathy with macroscopic hematuria post-URI

— Lupus nephritis activity

— New nephrotic syndrome — workup with serologies and consider biopsy

— SGLT2i continues but disease-specific therapy needed (steroids, immunosuppression)

— HF decompensation → venous congestion → worsening renal function

— Diuresis (loop) and SGLT2i continuation typically improve both

— NSAIDs — afferent constriction, AKI

— ACEi/ARB — efferent dilation, may compound SGLT2i hemodynamic dip

— Aminoglycosides, vancomycin, contrast — ATN

— PPIs, beta-lactams, sulfonamides — AIN with eosinophilia, pyuria

— Starvation ketosis (mild, HCO₃ usually preserved)

— Alcoholic ketoacidosis (history-dependent)

— Lactic acidosis (sepsis, metformin, ischemia)

— Each has distinct labs; SGLT2i eDKA has β-hydroxybutyrate dominance with anion gap

— Mycotic vs bacterial vulvovaginitis vs STI vs atrophic vaginitis — examine and test

Key distinction: A patient on empagliflozin with eGFR 38 → 32 over 6 weeks has an expected initiation dip — recheck and reassure. A drop to 22 with hyperkalemia and new edema suggests superimposed AKI or HF decompensation, not SGLT2i toxicity.

When a patient on SGLT2i has unexpectedly worsening eGFR or new symptoms, broaden beyond CKD progression

Acute kidney injury superimposed on CKD:

Glomerular disease flare:

Cardiorenal syndrome:

Hepatorenal syndrome: in cirrhotic patients — distinct pathophysiology, requires terlipressin/albumin

Drug-induced causes to distinguish from SGLT2i effect:

Euglycemic DKA mimics:

Genital symptoms differential:

Secondary Prevention, Discharge, and Long-Term Plan

— Confirm SGLT2i is on or off the discharge list based on clinical status

— If held for AKI or sepsis: document restart plan with PCP at 1–2 weeks if recovery confirmed

— If newly started: explicit dosing, indication, expected effects, side-effect counseling

— ACEi or ARB at max tolerated dose

— SGLT2 inhibitor (empagliflozin or dapagliflozin)

— Finerenone if T2DM + persistent albuminuria + K⁺ ≤4.8

— GLP-1 RA if T2DM with obesity, ASCVD, or refractory albuminuria

— Statin — moderate-to-high intensity for any CKD age 50–75 (KDIGO)

— Antiplatelet if ASCVD

— BP control <120/80 if tolerated

— A1c individualized

— Annual influenza

— Pneumococcal (PCV20 or PCV15+PPSV23)

— Hepatitis B (especially eGFR <30, anticipating dialysis)

— COVID-19 updated

— RSV if ≥60

— DASH-style diet, sodium <2 g/day, protein 0.6–0.8 g/kg

— Smoking cessation, alcohol moderation

— Aerobic + resistance exercise as tolerated

— Weight management

— Sick-day rules card listing meds to hold (SGLT2i, ACEi/ARB, metformin, diuretics, NSAIDs) during acute illness

— DKA symptom recognition

— Genital infection symptom recognition

Step 3 management: At hospital discharge after HF admission, a T2DM/CKD patient should leave on GDMT including SGLT2i, ARNI, beta-blocker, MRA, plus statin and ACEi for CKD/ASCVD — confirm follow-up within 7–14 days with weight log and BMP.

Whether prescribing in clinic or at hospital discharge, build a durable longitudinal plan — Step 3 hallmark

Discharge medication reconciliation:

Cardiorenal pillar checklist at discharge or in long-term plan:

Vaccinations (CKD-specific):

Lifestyle counseling:

Patient-held action plan:

Follow-Up, Monitoring Parameters, and Counseling

— 2–4 weeks: BMP (eGFR, K⁺, HCO₃), BP, weight, symptom check (orthostasis, genital infection)

— 3 months: A1c, UACR, BMP, weight, BP — assess response (UACR drop 30%+ favorable)

— 6 months and annually thereafter: lipids, A1c, UACR, BMP, fundoscopy in diabetics, foot exam

— G3a (eGFR 45–59): UACR + eGFR every 6–12 months

— G3b (30–44): every 4–6 months

— G4 (15–29): every 3 months, prepare for KRT planning at eGFR <20

— Annual DEXA, PTH, phosphorus, calcium, 25-OH vitamin D when eGFR <60

— Annual hemoglobin (anemia of CKD) — workup if Hb <11 women/<12 men, treat iron deficiency, ESA when Hb <10

— Successful response: UACR reduction ≥30%, BP at goal, stable eGFR trajectory after initial dip, weight loss 2–3 kg, A1c improvement

— Inadequate response: persistent UACR >300 → escalate (finerenone, GLP-1 RA)

— Reinforce sick-day rules

— Perioperative planning if surgery anticipated

— Hydration status check (not excessive water intake)

— Genital hygiene

— Hypoglycemia symptoms if on insulin/SU

— Pharmacy refill records, pill counts, patient self-report

— Address cost: manufacturer coupons, formulary alternatives

— Cardiac rehab if HF/ASCVD coexists

— Renal-specific dietary counseling (registered dietitian) when eGFR <45

— Mental health: depression screening (PHQ-9) — common in CKD and reduces adherence

Board pearl: At 3-month follow-up after starting empagliflozin, eGFR stabilizes after the initial 3–5 mL/min dip and UACR drops 30–40% — this is the expected and reassuring trajectory.

Visit cadence after SGLT2i initiation:

CKD-specific monitoring (KDIGO):

Response assessment:

Counseling at every visit:

Adherence assessment:

Rehabilitation and lifestyle:

Ethical, Legal, and Patient Safety Considerations

— Discuss expected benefits (slower CKD progression, reduced CV events, lower hospitalization) vs risks (DKA, genital infections, rare Fournier gangrene)

— Use number needed to treat (~20 over 2–3 years to prevent one composite kidney event in DAPA-CKD) when patients ask "will it really help me"

— Document discussion, especially in patients declining therapy

— Hospital-to-home transitions: SGLT2i held during admission for AKI or sepsis must have clear restart instructions in discharge summary; failure to restart appropriate GDMT is a measurable quality gap

— Perioperative: clear hold instructions 3–4 days pre-surgery; failure to hold = euglycemic DKA on POD 1–3

— Sick-day rules: medication action plan card; teach-back method

— Fournier gangrene is a sentinel event; report to FDA MedWatch and institutional safety committee

— Adverse drug events documented per institutional protocol

— SGLT2 inhibitors are brand-only and expensive — be aware of Medicare Part D coverage gaps, prior authorization burdens, and systematic underprescription in Black, Hispanic, and lower-income patients with CKD

— Advocate for formulary access; use patient assistance programs

— Document financial barriers in the chart

— CMS and NCQA increasingly include GDMT for CKD (ACEi/ARB + SGLT2i where indicated) as performance measures

— Frail nursing home patient: weigh benefit horizon against life expectancy; defer if <6 months

— Patient with severe medication nonadherence and recurrent DKA: weigh ongoing prescription vs harm

— Pregnancy planning: counsel in advance, switch to insulin

Step 3 management: A T2DM CKD patient was hospitalized for sepsis; SGLT2i was held. The discharge summary must include a scheduled PCP visit at 1–2 weeks, BMP recheck, and a clear plan to restart empagliflozin — omitting this is the patient-safety wrong answer.

Informed consent and shared decision-making:

Patient safety — transitions of care (Step 3 favorite):

Mandatory and event-based safety reporting:

Health equity and access:

Quality measures:

Ethical edge cases:

High-Yield Associations and Rapid-Fire Clinical Facts

Board pearl: The single highest-yield Step 3 fact: empagliflozin or dapagliflozin should be added to a maximally dosed ACEi/ARB in any CKD patient with eGFR ≥20 and UACR ≥200, regardless of diabetes status.

Initiation threshold: eGFR ≥20 mL/min/1.73 m²

Continuation: allowed down to dialysis initiation

First-line agents for CKD: empagliflozin or dapagliflozin

Expected eGFR dip: 3–5 mL/min in first 2–4 weeks, reversible, predicts long-term benefit

Expected UACR reduction: 30–40% at 3 months

A1c reduction: 0.3–0.7%, diminishes as eGFR falls

Weight loss: 2–3 kg

BP reduction: 3–5 mmHg systolic

DKA risk: highest with T1DM (contraindicated), illness, surgery, low-carb diets

Perioperative hold: 3 days (4 for ertugliflozin)

Pillars of diabetic CKD therapy: ACEi/ARB → SGLT2i → finerenone → GLP-1 RA

Trials: CREDENCE (canagliflozin, T2DM+CKD), DAPA-CKD (dapagliflozin, CKD ± DM), EMPA-KIDNEY (empagliflozin, broad CKD), DAPA-HF/EMPEROR (HF), FLOW (semaglutide kidney)

Black-box warnings: Fournier gangrene, DKA, lower-limb amputation (canagliflozin)

Contraindications: T1DM, eGFR <20 for initiation, pregnancy, breastfeeding, prior recurrent DKA

Genital mycotic infection: ~10% women, ~3% men — treat, don't stop

Hyperkalemia profile: K⁺-neutral or lowering — helpful with RAAS/MRA combinations

Hydration: normal intake; avoid excessive fluid loading

Statin indication in CKD: moderate-to-high intensity age ≥50

Vaccines: flu, pneumococcal, HBV, COVID-19, RSV if ≥60

Sick-day meds to hold (SADMANS): Sulfonylureas, ACEi/ARB, Diuretics, Metformin, SGLT2i, NSAIDs

Cardiac: SGLT2i benefits HFrEF AND HFpEF (unique among HF therapies)

Stop SGLT2i permanently for: Fournier gangrene, recurrent DKA, severe genital infection refractory to treatment

Board Question Stem Patterns

— 58 y/o T2DM, A1c 7.4%, BP 132/78 on lisinopril 40 + amlodipine, eGFR 52, UACR 380. What is the next best step?

— Answer: Add empagliflozin 10 mg daily.

— 64 y/o with IgA nephropathy, eGFR 38, UACR 700 on losartan 100. Next step?

— Answer: Add dapagliflozin 10 mg daily (DAPA-CKD applies regardless of diabetes).

— Patient started on SGLT2i 3 weeks ago; eGFR dropped from 45 to 41. Most appropriate action?

— Answer: Continue current therapy and recheck in 3 months — not discontinue, not refer.

— T2DM on empagliflozin + insulin, presents post-cholecystectomy with nausea, glucose 175, anion gap 22, ketones+. Diagnosis?

— Answer: Euglycemic DKA — IV fluids, insulin drip with concurrent dextrose, hold SGLT2i.

— Patient on dapagliflozin scheduled for elective hip replacement in 5 days. Best advice?

— Answer: Hold dapagliflozin 3 days before surgery, resume when eating and stable.

— HFrEF EF 30%, eGFR 32, on ACEi + beta-blocker + spironolactone + furosemide. Next step?

— Answer: Add empagliflozin 10 mg daily — benefits both axes.

— T2DM + CKD on lisinopril + empagliflozin, persistent UACR 600, K⁺ 4.4, eGFR 38. Next?

— Answer: Add finerenone 10 mg daily.

— T1DM patient with CKD asks about SGLT2i for kidney protection. Best response?

— Answer: Do not start; intensify insulin and optimize ACEi/ARB.

— Diabetic on canagliflozin with severe perineal pain, swelling, fever, crepitus. Next step?

— Answer: Emergent surgical consult, broad-spectrum antibiotics, ICU — Fournier gangrene; permanently discontinue SGLT2i.

— Patient on empagliflozin develops gastroenteritis with vomiting. Advice?

— Answer: Hold empagliflozin, ACEi, diuretic, metformin; hydrate; restart when eating normally.

Key distinction: The "wrong answer" pattern is usually stop the SGLT2i for the initiation eGFR dip or don't start because eGFR is 24. Recognize these as traps.

Stem 1 — The albuminuric T2DM patient:

Stem 2 — Non-diabetic CKD:

Stem 3 — The initiation dip trap:

Stem 4 — Euglycemic DKA:

Stem 5 — Perioperative management:

Stem 6 — HF + CKD overlap:

Stem 7 — Layering pillar:

Stem 8 — Contraindication recognition:

Stem 9 — Adverse event:

Stem 10 — Sick-day rules:

One-Line Recap

SGLT2 inhibitors (empagliflozin or dapagliflozin) are a pillar of CKD therapy, indicated for any patient with eGFR ≥20 plus diabetic kidney disease or albuminuric CKD (with or without diabetes), layered onto maximally tolerated ACEi/ARB, with expected mild initial eGFR dip, 30–40% UACR reduction, and major reductions in CKD progression, cardiovascular events, and mortality.

High-yield recap bullets:

— First-line agents: empagliflozin 10 mg daily or dapagliflozin 10 mg daily

— Expected eGFR dip 3–5 mL/min is reassuring, not a stop signal

Final Step 3 pearl: When in doubt on a CKD or HF vignette where the patient is on a maxed ACEi/ARB and is not on an SGLT2i, the answer is almost always add empagliflozin 10 mg daily — this single decision encapsulates contemporary cardiorenal medicine.

Indication memorized: eGFR ≥20 + (T2DM with any albuminuria) OR (any CKD with UACR ≥200) OR (HFrEF/HFpEF) — add to maxed ACEi/ARB; continue down to dialysis

Pillar sequencing in diabetic CKD: ACEi/ARB → SGLT2i → finerenone (if K⁺ ≤4.8, eGFR ≥25) → GLP-1 RA — each adds independent kidney and CV protection (CREDENCE, DAPA-CKD, EMPA-KIDNEY, FIDELIO, FLOW)

Safety essentials: Contraindicated in T1DM and pregnancy; hold 3–4 days pre-op and during acute illness (sick-day rules); recognize euglycemic DKA (anion gap acidosis with normal glucose) and Fournier gangrene (permanent discontinuation); reduce loop diuretic by 25–50% and insulin by 20% at initiation; monitor BMP at 2–4 weeks

Step 3 systems thinking: Document restart plans after hospital holds (transitions of care), counsel on sick-day rules with teach-back, address access barriers (cost, prior auth), and integrate with vaccinations, statins, and BP/glycemic targets in a longitudinal care plan